PTO/SB/30 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

| Under the Paperwork Reduction Act of 1995, no persons are requi  | U.S. Patent and T<br>ired to respond to a collection of inf      | rademark Office; U.S<br>ormation unless it or | S. DEPARTMENT OF COMMERCE<br>ontains a valid OMB control number. |
|--|--|---|--|
| Request  | Application Number   | 10/091,173                                    |  |
| for Continued Examination (RCE)  | Filing Date  | March 6, 200                                  | 02   |
| Transmittal  | First Named Inventor   | VONEIFF, J                                    | ohn  |
| Address to:<br>Mail Stop RCE   | Art Unit   | 3724  |  |
| Commissioner for Patents<br>P.O. Box 1450  | Examiner Name  | PRONE, Jas                                    | son D.   |
| Alexandria, VA 22313-1450  | Attorney Docket Numb   | er 62909.0000                                 | 03   |
| This is a Request for Continued Examination (RCE) of Request for Continued Examination (RCE) practice under 37 Cl 1995, or to any design application. See Instruction Sheet for RC                                   | FR 1,114 does not apply to an                                    | utility or plant ap                           | plication filed prior to June 8,                                 |
| <ol> <li>Submission required under 37 CFR 1.114 No<br/>amendments enclosed with the RCE will be entered in th<br/>applicant does not wish to have any previously filed uner<br/>amendment(s).</li> </ol>             | ne order in which they were file<br>ntered amendment(s) entered, | d unless applicant<br>applicant must re       | t instructs otherwise. If<br>quest non-entry of such             |
| <ul> <li>a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.</li> </ul>          |  |   |  |
| i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on   |  |   |  |
| ii Other<br>b.   |  |   |  |
| I. ✓ Amendment/Reply iii, Information Disclosure Statement (IDS)   |  |   |  |
| ii. Affidavit(s)/ Declaration(s) iv. V. Other Petition for two-month extension of time   |  |   |  |
| 2. Miscellaneous   |  |   |  |
| Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)               |  |   |  |
| b. Other   |  |   |  |
| 3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to |  |   |  |
| a. Deposit Account No. 50-0206 I have enclosed a duplicate copy of this sheet.   |  |   |  |
| i. RCE fee required under 37 CFR 1.17(e)  ii. Extension of time fee (37 CFR 1.136 and 1.17)  |  |   |  |
| iii.   Other \$225 For Small Entity Two Month Extension Of Time  |  |   |  |
| b. Check in the amount of \$enclosed   |  |   |  |
| c. Payment by credit card (Form PTO-2038 enclose   |  |   |  |
| WARNING: Information on this form may become public. C card information and authorization on PTO-2038.   | Credit card information shoul                                    | d not be include                              | d on this form. Provide credit                                   |
| SIGNATURE OF APPLICA   | ANT, ATTORNEY, OR AGEN   |   |  |
| Signature  |  | Date  | 12/26/2006   |
| Name (Print/Type) Robert A. King   |  | Registration No.                              | 42,738   |
| CERTIFICATE OF MAILING OR TRANSMISSION   |  |   |  |
|  |  |   |  |
| CERTIFICATE Co  I hereby certify that this correspondence is being deposited with the Unit addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 145  Office on the date shown below.                     | ited States Postal Service with suffi                            | cient postage as fire                         | t class mail in an envelope<br>to the U.S. Patent and Trademark  |

Name (Pietr/Type)

This collection of information is required by 37 CER 1.114. The information is required to obtain or retains a benefit by the public which is to file (and by the USPTO to process) an application. Confrientfally is governed by 36 U.S.C. 122 and 37 CER 1.114 and 1.14. This collection is estimated to take 12 minutes to complete to process) an application. Confrientfally is governed by 36 U.S.C. 122 and 37 CER 1.114 and 1.14. This collection is estimated to take 12 minutes to complete including gathering, prepagin, and sustaining the completed application from the USPTO. Time will very objecting upon the including allows of the confrience of the USPTO. The will very objecting upon the including allows of the process of the confrience of the USPTO. The value of the USPTO. The VISPTO. T

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# Instruction Sheet for RCEs (not to be submitted to the USPTO)

#### NOTES:

An RCE is not a new application, and filing an RCE will not result in an application being accorded a new filing date.

#### Filing Qualifications:

The application must be a utility or plant application filed on or after June 8, 1995. The application cannot be a provisional application, a utility or plant application filed before June 8, 1995, a design application, or a patent under reexamination. See 37 CFR 1.114(e).

#### Filing Requirements:

Prosecution in the application must be closed. Prosecution is closed if the application is under appeal, or the last Office action is a final action, a notice of allowance, or an action that otherwise closes prosecution in the application (e.g., an Office action under Exparte Quayle). See 37 CFR.114(b).

A submission and a fee are required at the time the RCE is filed. If reply to an Office action under 35 U.S.C. 132 is outstanding (e.g., the application is under final rejection), the submission must meet the reply requirements of 37 CFR 1.111. If there is no outstanding Office action, the submission can be an information disclosure statement, an amendment, new arguments, or new evidence. See 37 CFR 1.114(c). The submission may be a previously filed amendment (e.g., an amendment after final relaction).

### WARNINGS:

# Request for Suspension of Action:

All RCE filing requirements must be met before suspension of action is granted. A request for a suspension of action under 37 CFR 1.103(c) does not satisfy the submission requirement and does not permit the filing of the required submission to be suspended.

# Improper RCE will NOT toll Any Time Period:

Before Appeal - If the RCE is improper (e.g., prosecution in the application is not closed or the submission or fee has not been filed) and the application is not under appeal, the time period set forth in the last Office action will continue to run and the application will be abandoned after the statutory time period has expired if a reply to the Office action is not timely filed. No additional time will be diven to correct the improper RCE.

Under Appeal - If the RCE is improper (e.g., the submission or the fee has not been filed) and the application is under appeal, the improper RCE is effective to withdraw the appeal. Withdrawal of the appeal results in the allowance or abandomment of the application depending on the status of the claims. If there are no allowed claims, the application is abandomed. If there is at least one allowed claim, the application will be passed to issue on the allowed claim(s). See MPEP 1215.01.

See MPEP 706.07(h) for further information on the RCE practice.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 350 LSC. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration or the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an international Application filed under the Patent Cooperation Treaty in
  this system of records may be disclosed, as a routine use, to the International Bureau of the
  World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued natent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.